JCO Global Oncology (Jul 2022)

Impact of Molecular Tumor Board on the Clinical Management of Patients With Cancer

  • Vichitra Behel,
  • Vanita Noronha,
  • Anuradha Choughule,
  • Omshree Shetty,
  • Pratik Chandrani,
  • Akhil Kapoor,
  • Suresh Kumar Bondili,
  • Jyoti Bajpai,
  • Rajiv Kumar,
  • Trupti Pai,
  • Munita Bal,
  • Mamta Gurav,
  • Prachi Bapat,
  • Neha Mittal,
  • Santosh Menon,
  • Vijay Patil,
  • Nandini Menon,
  • Amit Dutt,
  • Kumar Prabhash

DOI
https://doi.org/10.1200/GO.22.00030
Journal volume & issue
no. 8

Abstract

Read online

PURPOSEMultidisciplinary molecular tumor boards (MTBs) help in interpreting complex genomic data generated by molecular tumor profiling and improve patients' access to targeted therapies. The purpose of this study was to assess the impact of our institution's MTB on the clinical management of patients with cancer.METHODSThis study was conducted at a tertiary cancer center in India. Cases to be discussed in the MTB were identified by molecular pathologists, scientists, or oncologists. On the basis of the clinical data and molecular test reports, a course of clinical management was recommended and made available to the treating oncologist. We determined the proportion of patients who were recommended a change in the clinical management. We also assessed compliance of the treating oncologists with MTB recommendations.RESULTSThere were 339 discussions for 328 unique patients. The median age of the cohort was 54 years (range 17-87), and the majority of the patients were men (65.1%). Of 339 cases, 133 (39.2%) were recommended continuation of ongoing therapy while the remaining 206 (60.7%) were recommended a change in clinical management. Compliance with MTB recommendations for a change in clinical management was 58.5% (79 of 138 evaluable cases). Compliance and implementation for MTB's recommendation to start a new therapy in 104 evaluable cases were 60.5% and 44.2%, respectively. A total of 248 biopsies had at least one actionable mutation. A total of 646 mutations were identified in the cohort, with EGFR being the most frequently altered gene.CONCLUSIONMTBs help in interpreting results of molecular tests, understanding the significance of molecular abnormalities, and assessing the benefits of available targeted therapies and clinical trials in the management of patients with targetable genetic alterations.